Welcome to our dedicated page for EASTMAN CHEMICAL CO SEC filings (Ticker: EMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EASTMAN CHEMICAL CO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EASTMAN CHEMICAL CO's regulatory disclosures and financial reporting.
SLAGER DONALD W reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical Company director Donald W. Slager received an equity grant of 1,628 shares of common stock. This was a grant or award, not an open-market purchase or sale, and carried a price of $0.00 per share as compensation rather than a cash transaction.
The shares are restricted, with restrictions scheduled to lapse on May 7, 2027, subject to conditions tied to his continued service as a director. Following this grant, Slager directly holds a total of 3,303 shares of Eastman Chemical common stock.
Holder Julie Fasone reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Julie Fasone Holder received a grant of 1,628 shares of common stock as a restricted stock award. The shares were granted at no cash cost and will remain restricted until May 7, 2027, contingent on her continued service as a director. Following this award, she directly holds 19,174 shares of Eastman Chemical common stock.
Eastman Chemical Company director Renee J. Hornbaker received a grant of 1,628 shares of common stock as a restricted stock award. The restrictions are scheduled to lapse on May 7, 2027, subject to her continued service as a director. Following this award, she directly holds 25,565 shares, which include 154 shares acquired through automatic dividend reinvestment since May 1, 2025.
OBRIEN JAMES J /KY reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director James J. O'Brien received a grant of 1,628 shares of common stock as a restricted stock award. The award was granted at no cash cost and represents his annual Restricted Stock Award. After this grant, he holds 8,456 shares directly.
The restricted shares are scheduled to lapse on May 7, 2027, subject to conditions tied to his continued service as a director. In addition to his direct holdings, he also indirectly owns 1,022 shares through a revocable trust.
BUTLER ERIC L reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Eric L. Butler received a grant of 1,628 shares of common stock as a restricted stock award. The shares were awarded at no cash cost per share and represent his annual Restricted Stock Award as a director. Following this grant, Butler directly holds 10,958 shares of Eastman Chemical common stock. The restrictions on these shares will lapse on May 7, 2027, subject to conditions tied to his continued service as a director.
Eastman Chemical Company director Linnie M. Haynesworth received an annual equity grant in the form of restricted common shares. On May 7, 2026, she acquired 1,628 shares at no cash price as a grant or award, increasing her direct holdings to 3,135 shares. These are restricted shares, with restrictions scheduled to lapse on May 7, 2027, subject to conditions related to her continued service as a director. The share amount represents her annual Restricted Stock Award, reflecting routine director compensation rather than an open-market purchase or sale.
Audia Damon J reported acquisition or exercise transactions in this Form 4 filing.
Eastman Chemical director Damon J. Audia reported a compensation-related grant of 1,628 Phantom Stock Units on May 7, 2026. These units, each valued at $73.69, are credited under the Directors' Deferred Compensation Plan and bring his total phantom units to 4,274.
The units will vest on May 7, 2027 and are payable only in cash, not stock. According to the footnotes, this represents a deferral of the value of his annual non-employee director restricted stock award that otherwise would have been paid in common shares, making this a routine, non-market transaction.
Eastman Chemical Company senior vice president Adrian James Holt reported selling common stock and settling deferred compensation units. On May 5, 2026, he executed an open-market sale of 1,709 shares of common stock at $77.05 per share, leaving no directly held shares from this position in the filing. The same day, he disposed of 2,271 Phantom Stock Units to the issuer under an Executive Deferred Compensation Plan, each unit valued based on the closing price of Eastman Chemical common stock on the disposition date, also leaving no remaining units from this grant.
Eastman Chemical Company reported weaker results for the first quarter of 2026. Sales decreased 5% to $2,177 million from $2,290 million a year earlier, as lower volumes and prices, especially in Chemical Intermediates and Fibers, outweighed modest foreign-exchange benefits.
Net earnings attributable to Eastman fell to $107 million from $182 million, and diluted EPS declined to $0.93 from $1.57. On an adjusted basis, excluding restructuring and tax items, EPS was $1.09 versus $1.91. Gross profit dropped to $431 million from $567 million, reflecting weaker pricing, demand and lower asset utilization.
By segment, Adjusted EBIT declined sharply in Advanced Materials and Fibers, while Additives & Functional Products held roughly flat and Chemical Intermediates swung to a loss. The company recognized a $22 million benefit from expected refunds of invalidated IEEPA tariffs, partially offsetting Winter Storm–driven energy costs.
Operating cash flow was a use of $137 million, similar to the prior-year outflow, largely due to working capital swings. Eastman issued $600 million of 4.5% notes due 2031 (net proceeds $594 million) and repaid the remaining $150 million on a 2027 term loan, ending the quarter with $665 million in cash and total borrowings of $5,220 million.